ProKidney Past Earnings Performance
Past criteria checks 0/6
ProKidney has been growing earnings at an average annual rate of 42.9%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
42.9%
Earnings growth rate
78.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -34.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How ProKidney makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -35 | 45 | 107 |
| 30 Sep 23 | 0 | -36 | 52 | 105 |
| 30 Jun 23 | 0 | 56 | 52 | 94 |
| 31 Mar 23 | 0 | 43 | 48 | 79 |
| 31 Dec 22 | 0 | -14 | 71 | 82 |
| 30 Sep 22 | 0 | -22 | 65 | 72 |
| 30 Jun 22 | 0 | -31 | 53 | 65 |
| 31 Mar 22 | 0 | -111 | 45 | 65 |
| 31 Dec 21 | 0 | -55 | 9 | 46 |
| 30 Sep 21 | 0 | -49 | 7 | 42 |
| 31 Dec 20 | 0 | -27 | 6 | 21 |
Quality Earnings: PROK is currently unprofitable.
Growing Profit Margin: PROK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PROK is unprofitable, but has reduced losses over the past 5 years at a rate of 42.9% per year.
Accelerating Growth: Unable to compare PROK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PROK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: PROK has a negative Return on Equity (-34.61%), as it is currently unprofitable.